nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-A0D3875D·Framework v5.13·Pipeline v0.4·Evaluated 13 Nov 2026·OECD: 3.1 Basic medicine·Subfield: Genetics (clinical)·Basis: Full text·Type: Laboratory experiment

Defective Lysosomal Lipolysis Causes Prenatal Lipid Accumulation and Exacerbates Immediately after Birth.

Kuentzel et al.Kuentzel, Bradić, Akhmetshina et al.·2021·International journal of molecular sciences·10.3390/ijms221910416 ↗

Primary claim

defective lysosomal but not neutral lipolysis alters placental and fetal cholesterol homeostasis and exhibits an initial disease pathology already in utero as Lal-/- fetuses accumulate hepatic lysosomal lipids.

Tentative · the HSL comparison does not establish absence of metabolic effects, despite convergent evidence for prenatal LAL-associated lipid accumulation
In brief

Developmental profiling establishes prenatal lipid accumulation and rapid postnatal worsening in LAL-deficient mice, but overstates the absence of HSL-related effects.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Possible — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Cholesterol and fatty acids are essential lipids that are critical for membrane biosynthesis and fetal organ development. Cholesteryl esters (CE) are degraded by hormone-sensitive lipase (HSL) in the cytosol and by lysosomal acid lipase (LAL) in the lysosome. Impaired LAL or HSL activity causes rare pathologies in humans, with HSL deficiency presenting less severe clinical manifestations. The infantile form of LAL deficiency, a lysosomal lipid storage disorder, leads to premature death. However, the importance of defective lysosomal CE degradation and its consequences during early life are incompletely understood. We therefore investigated how defective CE catabolism affects fetus and infant maturation using Lal and Hsl knockout (-/-) mouse models. This study demonstrates that defective lysosomal but not neutral lipolysis alters placental and fetal cholesterol homeostasis and exhibits an initial disease pathology already in utero as Lal-/- fetuses accumulate hepatic lysosomal lipids. Immediately after birth, LAL deficiency exacerbates with massive hepatic lysosomal lipid accumulation, which continues to worsen into young adulthood. Our data highlight the crucial role of LAL during early development, with the first weeks after birth being critical for aggravating LAL deficiency.

Key Claims

Primary finding · Tentative

defective lysosomal but not neutral lipolysis alters placental and fetal cholesterol homeostasis and exhibits an initial disease pathology already in utero as Lal-/- fetuses accumulate hepatic lysosomal lipids.

Possible — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

the HSL comparison does not establish absence of metabolic effects, despite convergent evidence for prenatal LAL-associated lipid accumulation

Abstract
Quote verified
Secondary · Supported

Immediately after birth, LAL deficiency exacerbates with massive hepatic lysosomal lipid accumulation, which continues to worsen into young adulthood.

age-specific measurements support worsening, although different animals and genotype-relative lipid values limit direct assessment of progression

Abstract; Sections 2.5–2.6
Quote verified
Secondary · Tentative

HSL deficiency has little effect on placental and fetal development and does not interfere with placental lipid metabolism.

uncertain maternal comparability and changed placental gene expression prevent the negative comparison from establishing no metabolic effect

Introduction, final paragraph; Section 2.2
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Convergent measurements identify prenatal lipid accumulation

Lipid quantification, enzyme assays, lysosomal staining, and electron microscopy converge on prenatal abnormalities in LAL-deficient tissues. These complementary measurements support the central LAL phenotype.

↳ Results Sections 2.3–2.4; Methods Sections 4.4–4.7

#contribution

Developmental sampling extends established disease models

Sampling at late gestation, two days, two weeks, and four weeks establishes an early-life disease profile beyond the adult phenotypes emphasized in prior mouse work.

↳ Results Sections 2.3–2.6; Discussion

#positioning

Discussion considers maternal and dietary influences

The interpretation explicitly considers active LAL supplied by heterozygous mothers and dietary changes around birth and weaning. Prenatal human case reports also place the mouse findings in clinical context.

↳ Discussion

Limitations

#methodological rigour

Bias safeguards and replicate units remain unclear

Blinded assessment of histology and electron microscopy is not reported. The statement that samples came from different dams does not explicitly define the statistical unit or explain handling of multiple littermates.

↳ Methods Sections 4.1, 4.4, 4.7–4.8

#reporting

HSL no-effect wording exceeds measured evidence

The broad claim that HSL deficiency does not interfere with placental lipid metabolism exceeds the unchanged lipid concentrations: neutral CE hydrolase activity fell 35%, and cholesterol-synthesis gene expression fell more than 50%.

↳ Abstract; Introduction, final paragraph; Results Section 2.2

#methodological rigour

HSL controls lack established maternal comparability

The reported HSL breeding cross cannot produce wild-type offspring, leaving the source of wild-type comparators and their maternal comparability unresolved. This limits interpretation of the negative HSL comparison.

↳ Methods Section 4.1; Results Section 2.2

Does this match your read? Add your assessment ↓

Nabu Commentary

The prenatal LAL phenotype rests on complementary biochemical and microscopy observations, and the developmental sampling extends an established disease model into early life. Execution is less secure where blinded assessment and the analyzed replicate unit are not explicitly reported. The HSL comparison has an unresolved control-source issue, while its broad no-effect wording overlooks reported changes in enzyme activity and cholesterol-synthesis gene expression. The Discussion engages prior mouse and human findings and considers maternal enzyme supply and dietary transitions without experimentally separating these explanations.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.4±0.2

Contribution
3.7

The study extends established knockout phenotypes into late gestation and the first four postnatal weeks, documenting prenatal LAL-associated lipid accumulation. Its advance is developmental characterization rather than a tested molecular mechanism or intervention.

Results Sections 2.3–2.6; Discussion
Methodological Rigour
3.1

Biochemical lipid measurements, enzyme assays, staining, and electron microscopy provide convergent evidence, with littermate controls in the LAL arm. Unreported blinding, an incompletely specified replicate unit, and uncertain maternal comparability of HSL controls introduce meaningful uncertainty.

Results Sections 2.2–2.6; Methods Sections 4.1, 4.4–4.8
Reporting
3.4

The fetal-to-postnatal sequence makes the developmental argument accessible. Central statements excluding an HSL effect are broader than the measured lipid endpoints and accompanying changes in activity and gene expression support.

Abstract; Introduction, final paragraph; Results Section 2.2
Positioning
3.6

The Discussion relates the findings to adult mouse studies, earlier reports of normal appearance at birth, and prenatal human cases. Maternal LAL supply and dietary transitions are considered, but uncertainty in the HSL comparison is not fully traced through the conclusions.

Discussion; Methods Section 4.1

Reliability

No concerns4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyClean

Animal ethics approval is declared with permit identifiers. Explicitly unshown and unpublished observations limit verification but do not independently establish a conduct concern.

Ethics approval: declared

Reference IntegrityClean

48 of 48 checkable references verified

48 references in manuscript

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 13 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useNot stated
AdvanceExtends
BeneficiariesCatch-all cause
CitationsFWCI 2.6
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim is demonstrated in genetically controlled knockout mouse models under laboratory conditions, showing lipid accumulation in fetal livers without any human validation.

The paper describes disease progression in a mouse model without stating any real-world use of its own findings beyond improved understanding of LAL deficiency timing.

Pathway

Understanding that LAL deficiency manifests prenatally could eventually inform clinicians on timing of diagnosis and enzyme replacement therapy initiation for affected infants.

Barrier

Findings are from a single mouse strain and require confirmation in human LAL-deficient pregnancies before informing any clinical prenatal or neonatal management decisions.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson's disease

    Sheshadri, Costa-Besada, Fisher, et al. · 2026 · Clinical medicine

    Primary claim

    the disruption of V-ATPase assembly driven by MTORC1 activation impairs lysosomal acidification. This causes impairment of mitophagy, leading to mitochondrial dysfunction

    Tentative
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  2. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  3. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats

How the rubric works →